Table 1.
Baseline characteristics.
| Characteristics | Positive TST and QFT-G | Positive TST and negative QFT-G | Negative TST and positive QFT-G | Negative TST and QFT-G | Total |
|---|---|---|---|---|---|
| Avg. age (years) | 59.8 | 61.0 | 54.5 | 53.5 | 54.9 |
| Std. deviation (years) | 13.1 | 11.2 | 13.8 | 11.3 | 12.2 |
| Male, n (%) | 3 (2%) | 1 (1%) | 1 (1%) | 12 (9%) | 17 (13%) |
| Female, n (%) | 12 (9%) | 7 (5%) | 26 (20%) | 70 (53%) | 115 (87%) |
| Hispanic, n (%) | 13 (10%) | 7 (5%) | 22 (17%) | 58 (44%) | 100 (76%) |
| Non-Hispanic, n (%) | 2 (2%) | 1 (1%) | 5 (4%) | 24 (18%) | 32 (24%) |
| SS∗, n (%) | 6 (5%) | 3 (2%) | 9 (7%) | 15 (11%) | 33 (25%) |
| DMARDs∗, n (%) | 13 (10%) | 7 (5%) | 25 (19%) | 75 (57%) | 120 (91%) |
| BRMs∗, n (%) | 7 (5%) | 2 (2%) | 12 (9%) | 28 (21%) | 49 (37%) |
| No drugs, n (%) | 1 (1%) | 0 (0%) | 1 (1%) | 6 (5%) | 8 (6%) |
| DMARDs∗ + SS∗ + BRMs∗, n (%) | 5 (4%) | 2 (2%) | 8 (6%) | 19 (14%) | 34 (26%) |
| DMARDs∗ + BRMs∗, n (%) | 7 (5%) | 2 (2%) | 12 (9%) | 28 (21%) | 49 (37%) |
∗SS: history of significant steroid use, DMARDs: disease modifying antirheumatic drugs, BRMs: Biologic Response Modifiers, and n: number.